Artivion (NYSE:AORT) EVP Sells $187,235.79 in Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 4,981 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $37.59, for a total transaction of $187,235.79. Following the sale, the executive vice president owned 148,450 shares in the company, valued at $5,580,235.50. This trade represents a 3.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Artivion Stock Up 1.1%

Artivion stock opened at $38.52 on Friday. The company has a 50 day moving average of $41.93 and a 200-day moving average of $43.02. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.25. The stock has a market capitalization of $1.84 billion, a PE ratio of 192.58 and a beta of 1.59.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm’s revenue was up 19.2% on a year-over-year basis. On average, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on AORT. Oppenheimer reiterated an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Needham & Company LLC restated a “buy” rating and issued a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Finally, Canaccord Genuity Group cut their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and an average price target of $48.97.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AORT. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion during the 3rd quarter worth approximately $27,000. Aster Capital Management DIFC Ltd grew its stake in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares in the last quarter. Larson Financial Group LLC increased its holdings in Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. USA Financial Formulas raised its position in Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after acquiring an additional 703 shares in the last quarter. Finally, KBC Group NV bought a new stake in Artivion during the fourth quarter worth $65,000. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.